CCL2, CCL8, CXCL12 chemokines in resectable non-small cell lung cancer (NSCLC)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F23%3A10001185" target="_blank" >RIV/00064190:_____/23:10001185 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/23:10453593 RIV/00216208:11120/23:43925032
Result on the web
<a href="https://biomed.papers.upol.cz/artkey/bio-202304-0004_ccl2-ccl8-cxcl12-chemokines-in-resectable-non-small-cell-lung-cancer-nsclc.php" target="_blank" >https://biomed.papers.upol.cz/artkey/bio-202304-0004_ccl2-ccl8-cxcl12-chemokines-in-resectable-non-small-cell-lung-cancer-nsclc.php</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5507/BP.2022.050" target="_blank" >10.5507/BP.2022.050</a>
Alternative languages
Result language
angličtina
Original language name
CCL2, CCL8, CXCL12 chemokines in resectable non-small cell lung cancer (NSCLC)
Original language description
Background. Complex networks of chemokines are part of the immune reaction targeted against tumor cells. Chemokines influence cancer growth. It is unclear whether the concentrations of chemokines at the time of NSCLC (non-small cell lung cancer) diagnosis differ from healthy controls and reflect the extent of NSCLC. Aims. To compare chemokine concentrations (CCL2, CCL8, CXCL12) in the plasma of patients with resectable NSCLC to those without cancer. To determine whether the chemokine concentrations differ relative to the stage of disease. Methods. Sixty-nine patients undergoing surgery for proven/suspected NSCLC were enrolled. They underwent standard diagnostic and staging procedures to determine resectability, surgery was performed. Forty-two patients were diagnosed with NSCLC, while 27patients had benign lung lesions and functioned as the control group. Chemokine concentrations in peripheral blood were assessed using ELISA. Parametric statistics were used for the analysis of results. Results. There were no differences in plasma chemokine concentrations in NSCLC patients compared to controls. CXCL12 concentrations correlated positively with tumor extent expressed as clinical stage, (mean values: stage I 5.08 ng/mL, SEM 0.59; stage II and IIIA 7.82 ng/mL; SEM 1.06; P=0.022). Patients with NSCLC stages II+IIIA had significantly higher CXCL12 concentrations than controls (mean values: stage II+IIIA 7.82 ng/mL; SEM 1.06; controls 5.3 ng/mL; SEM 0.46; P=0.017). Conclusion. CXCL12 was related to tumor growth and could potentially be used as a biomarker of advanced disease. (C) 2023 The Authors.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30203 - Respiratory systems
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
BIOMEDICAL PAPERS-OLOMOUC
ISSN
1213-8118
e-ISSN
—
Volume of the periodical
167
Issue of the periodical within the volume
4
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
5
Pages from-to
335-339
UT code for WoS article
000917083600001
EID of the result in the Scopus database
2-s2.0-85179772822